Kristin Stafford has been appointed Executive Vice President, Chief Financial Officer, effective April 1, 2026. Ms. Stafford will assume duties as the company's principal financial officer and principal accounting officer. She previously served as Senior Vice President, Chief Accounting Officer for Royalty Pharma plc since December 2018, and held finance roles at BioPharma Credit plc and Ernst & Young LLP Capital Markets. Her compensation package includes an annual base salary of $520,000, an initial target annual discretionary bonus of up to 45% of her base salary, and a $52,000 signing bonus. Equity awards include options to purchase 178,000 shares of common stock and 119,000 restricted stock units (RSUs) vesting over four years, plus an additional 50,000 RSUs vesting over three years. Kenneth Galbraith ceased serving as interim Chief Financial Officer but continues in his roles as Chair of the Board, Chief Executive Officer, and President.